News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on EBR Systems.
RELATED STOCKHEAD STORIES
News
Top 10 at 11: A mixed morning for lithium news and graphene is still on the boil
Health & Biotech
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as big names ‘trading at very attractive fundamentals’
Health & Biotech
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Health & Biotech
ScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall as CSL faces FX headwinds
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
Dr Boreham’s Crucible: EBR’s successful safety test looks like a proper heartstarter
Health & Biotech
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Health & Biotech
Pop the champagne as EBR becomes latest ASX biotech to achieve key catalyst
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as Proteomics inks Sonic deal
Health & Biotech
ScoPo’s (he’s back) Powerplays: ASX health stocks fall, Volpara ‘elephants’ strategy pays off
Health & Biotech
ScoPo’s (actually still Iain’s) Powerplays: ASX health sector falls, but several stocks on upward run
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update
News
After Neuren’s success, which other ASX health stocks are knocking on the US FDA door?
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but keep watchful eye on upcoming catalysts
Health & Biotech
